Biologic Therapy for Asthma & COPD: 8 Questions on Targets, Pathways, & mAbs

News
Article

Research into biologic therapy for asthma and COPD has been both successful and frustrating. Find out what you know about the progress with these 8 questions.

Ongoing research into the use of biologic therapies for patients with asthma and chronic obstructive pulmonary disease (COPD) has produced mixed results to date with promise for the future.

Take this quick quiz to test your knowledge of key developments of the past few years.

Newsletter

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!
Recent Videos
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Related Content
Digital Asthma Self Management Program Improves Symptom Control But Disparities in Benefit Are Clear / image credit Elevance Health

Digital Asthma Self Management Program Improves Symptom Control But Disparities in Benefit Are Clear

Grace Halsey
July 18th 2025
Article

A smartphone-based asthma management program significantly enhanced symptom control, but may require engagement or cultural tailoring to expand the effect.

Respiratory Tripledemic 2022-23: An Expert Recap

Respiratory Tripledemic 2022-23: An Expert Recap

Sydney Jennings
April 6th 2023
Podcast

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

Circulating Inflammatory Cells Persist in Severe Asthma Despite Biologic Therapy, Study Shows / image courtesy of Karolinska Institutet

Circulating Inflammatory Cells Persist in Severe Asthma Despite Biologic Therapy, Study Shows

Grace Halsey
July 2nd 2025
Article

Research from the Karolinska Institute reveals that therapies such as dupilumab and mepolizumab may not eliminate Th2 lymphocytes, raising concerns about long-term remission.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Sydney Jennings
May 20th 2022
Podcast

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

/ image credit Cathy Goldstein, MD Courtesy of Michigan Neuroscience Institute

Validation Study of SANSA Home Sleep Apnea Test Published in Frontiers in Neurology, Huxley Medical Announces

Grace Halsey
June 18th 2025
Article

Huxley Medical's SANSA home sleep apnea test matched traditional PSG in accuracy and significantly simplifies OSA assessment and diagnosis for patients and HCPs.

Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma

Rademikibart Demonstrates Improved Lung Function, Reduced Exacerbations in People with Eosinophilic-Driven Type 2 Asthma

Sydney Jennings
June 17th 2025
Article

EAACI 2025. New data revealed the effectiveness of rademikibart in improving lung function and reducing asthma exacerbations in patients with eosinophilic-driven type 2 asthma.

© 2025 MJH Life Sciences

All rights reserved.